MorphoSys AG
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP's AI-driven Unison Planning(TM) Platform Enhances Supply Chain Agility for McCormick & Co.3.12.2025 15:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / December 3, 2025 / OMP is helping McCormick & Co., the global leader in flavor, with an AI-driven and autonomous operational planning initiative. This partnership enables McCormick to manage both assembly-to-order (ATO) and make-to-stock (MTS) production within the Unison PlanningTM platform. The initiative tackles key challenges, including balancing ATO and MTS production on shared lines, improving inventory projections through quality-based stock releases, and managing capacity amid fluctuating demand. Addressing these challenges requires close collaboration across regions with North American and EMEA teams working in parallel, and seamless integration of SAP with the operational planning functionality within Unison Planning™. The first implementations will roll out in Canada and the United States before expanding to the EMEA and APAC regions. Through its partnership with OMP, McCormick is implementing autonomous, decision-centric planning powered
Oman's 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access3.12.2025 14:00:00 CET | Press release
Built for investors who value certainty, global access, and long-term confidence. MUSCAT, OM / ACCESS Newswire / December 3, 2025 / Three months after its introduction, Oman's 10-Year Golden Residency is emerging as one of the region's most compelling long-term residency pathways, attracting rising interest from investors, entrepreneurs, and internationally mobile families seeking stability, transparent regulation, and strategic access to high-growth markets. The programme-launched under Oman Vision 2040-offers a structured framework for investors wishing to establish deeper roots in a country positioning itself as a secure and globally connected economic hub.Prosperity and Liveability in Oman.jpg A contemporary Omani setting featuring growth, safety, and quality-of-life elements that define the country's reputation for prosperity and liveability. The Golden Residency grants eligible applicants long-term residency in return for a minimum investment of USD 520,000 across seven clearly d
Visit Qatar Presents Ludovico Einaudi Live in Doha3.12.2025 13:33:00 CET | Press release
DOHA, QA / ACCESS Newswire / December 3, 2025 / Visit Qatar presents one of the world's most celebrated composers and pianists, Ludovico Einaudi, to perform live in Doha on 9 January 2026 at the iconic Katara Amphitheatre. Doors open at 20:00 for an evening promising an extraordinary blend of emotion, artistry, and world-class music. Tickets are available at: https://doha.platinumlist.net/event-tickets/102626/ludovico-einaudi Known for his minimalist yet deeply evocative compositions, Ludovico Einaudi has captured global audiences with performances that seamlessly fuse classical tradition with contemporary sensibilities. His music, featured in internationally acclaimed films such as Nomadland and The Intouchables, has made him one of the most-streamed classical musicians worldwide. As Qatar continues to attract visitors from the region and around the world, the highly anticipated Ludovico Einaudi concert reflects Visit Qatar's commitment to hosting world-renowned talent and delivering
Nittetsu Mining Provides Final $1.5 Million Earn-in Payment for Camino's Los Chapitos Copper Project in Peru3.12.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / December 3, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the receipt of the sixth, and final, CAD$1.5 million payment from its exploration partner Nittetsu Mining CO., Ltd. ("Nittetsu"), marking the successful completion of Nittetsu's earn-in expenditure requirements under the earn-in agreement dated June 13, 2023 ("Earn-In Agreement") (see news release dated June 14, 2023). Following the conclusion of the current drilling program at the Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru, the Project will be formally converted into a joint venture, with Camino retaining a 65% participating interest, operatorship of the Project, and 50% of the life-of-mine production off-take. Los Chapitos is the second joint venture project with Nittetsu, as Camino is currently advancing the Puquios copper mine development with Nittetsu in Chile. At Los Chapitos, exploration drilling has
GoodData Ushers in Era of Governed and Trustworthy AI Analytics3.12.2025 11:00:00 CET | Press release
New Intelligence Layer allows enterprises to ground AI in governed data, ensuring precision, explainability, and confidence in every decision. SAN FRANCISCO, CA / ACCESS Newswire / December 3, 2025 / GoodData, leader in AI analytics and data intelligence, today announced the launch of its Intelligence Layer, a suite of governed, context-aware AI capabilities that bridge the gap between raw data and trustworthy, action-ready intelligence. Built for organizations operating across complex data environments, whether on-premises or across cloud services, the Intelligence Layer ensures that AI is grounded in a company's own rules, logic, and semantic definitions. Roman Stanek, CEO of GoodData, says: "Most companies don't need more dashboards; they need clarity. They need to know their data is right, easy to understand, and ready to use. That's exactly what the Intelligence Layer is built for." The Intelligence Layer embeds governance and business context directly into the analytical process,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom